XML 55 R46.htm IDEA: XBRL DOCUMENT v3.23.3

Collaboration Agreements, License Agreement and Revenues - Eluminex Agreement - Additional Information 2 (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended					9 Months Ended
	Jul. 31, 2021	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Apr. 30, 2023
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Total revenue		$ 40,134			$ 15,735		$ 120,614	$ 106,367
Eluminex [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Aggregate consideration received for milestone and upfront payments	$ 8,000
Future manufacturing clinical regulatory and commercial milestone payments	64,000
Commercial milestone	$ 36,000
Additional upfront payments									$ 1,500
Upfront payment		$ 500	$ 1,000
Eluminex [Member] | Cornea Products [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Percentage of product manufacturing costs until manufacturing technology fully transferred						10.00%
China [Member] | Eluminex [Member] | Biosynthetic Cornea [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Milestone Payments				$ 3,000
Manufacturing related milestone payments				$ 3,000

X

- Definition

Collaborative arrangement additional upfront payments.

+ References

No definition available.

+ Details

Name:	fgen_CollaborativeArrangementAdditionalUpfrontPayments
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Collaborative arrangement aggregate consideration for milestone and upfront payments.

+ References

No definition available.

+ Details

Name:	fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Commercial milestone.

+ References

No definition available.

+ Details

Name:	fgen_CommercialMilestone
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Future manufacturing clinical regulatory and commercial milestone payments.

+ References

No definition available.

+ Details

Name:	fgen_FutureManufacturingClinicalRegulatoryAndCommercialMilestonePayments
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Manufacturing related milestone payment.

+ References

No definition available.

+ Details

Name:	fgen_ManufacturingRelatedMilestonePayments
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Milestone payments.

+ References

No definition available.

+ Details

Name:	fgen_MilestonePayments
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Percentage of product manufacturing costs until manufacturing technology fully transferred.

+ References

No definition available.

+ Details

Name:	fgen_PercentageOfProductManufacturingCostsUntilManufacturingTechnologyFullyTransferred
Namespace Prefix:	fgen_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Upfront payment.

+ References

No definition available.

+ Details

Name:	fgen_UpfrontPayment
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_LicenseAgreementWithEluminexMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=fgen_CorneaProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=country_CN
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=fgen_BiosyntheticCorneaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: